RxDoctor Payments Data

Vickie Turnbough, MD

Internal Medicine · Athens, TNNPI 1508883612

Payments from drug & device makers

$6,631in general payments, 2019–2025

Across 436 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$893
  • Novo Nordisk$766
  • AstraZeneca$584
  • Boehringer Ingelheim$415
  • Bayer$393
  • AbbVie$354
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,615100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,631 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$136,390
Medicare patients
279
Services billed
2,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$130,820
MounjaroTirzepatide108$114,158
JardianceEmpagliflozin106$84,760
OzempicSemaglutide58$79,614
FarxigaDapagliflozin Propanediol108$63,723
XareltoRivaroxaban67$44,654
GlyxambiEmpagliflozin/Linagliptin30$39,896
RybelsusSemaglutide24$38,061
LinzessLinaclotide47$34,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,939
Repatha SureclickEvolocumab36$28,182
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$21,927
RexultiBrexpiprazole21$20,687
Breo ElliptaFluticasone/Vilanterol46$20,159
Lagevrio (Eua)Molnupiravir23$18,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat, Tradjenta$415$148,870174 claims
PfizerEliquis, Premarin$267$136,418268 claims
Lilly USA, LLCMounjaro, Trulicity$893$132,006124 claims
Novo NordiskOzempic, Rybelsus$766$117,67482 claims
AstraZenecaFarxiga, Breztri Aerosphere$584$82,434146 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$45$72,025105 claims
AbbVieLinzess, Savella$354$47,66564 claims
Johnson & JohnsonXarelto$191$44,65467 claims
MerckLagevrio (Eua), Januvia$75$36,24436 claims
Otsuka America Pharmaceutical, Inc.Rexulti$198$20,68721 claims
NovartisEntresto$138$16,41630 claims
BayerKerendia$393$7,85712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Athens

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →